Dexamethasone augmentation in treatment‐resistant depression
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A total of 10 patients who fulfilled DSM‐III‐R criteria for major depression were recruited to the study, each of whom had failed to respond to a 6‐week course of treatment with either sertraline or fluoxetine. Each subject had baseline serum cortisol measurements together with a Hamilton depression (HAMD) score. All patients were started on dexamethasone (3 mg daily) for 4 days, while remaining on their antidepressant treatment. Further Hamilton ratings were made on days 5 and 21. Six patients showed a significant improvement, whilst two showed a minimal response. A good clinical response was associated with a high baseline cortisol level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of major depression with steroid suppressive drugs
Pearson Murphy, B. E. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90069-h · Cited by 67
Cited by
The stress system in the human brain in depression and neurodegeneration
Swaab, D. F., Bao, A.-M., & Lucassen, P. J. (2005) · Ageing Research Reviews · doi:10.1016/j.arr.2005.03.003 · Cited by 984
“…in mood occurred in patients with treatment-resistant depression who received dexamethasone while remaining on their antidepressant (sertraline or fluoxetine) treatment supports the concept of hyperactive CRH neurons playing a causal role in the symptomatology of depression (Dinan et al., 1997).”
BackgroundThe glucocorticoid receptor: Pivot of depression and of antidepressant treatment?
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.03.007 · Cited by 592
The stress system in depression and neurodegeneration: Focus on the human hypothalamus
Bao, A.-M., Meynen, G., & Swaab, D. F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.04.005 · Cited by 548
Cortisol and depression: three questions for psychiatry
Herbert, J. (2013) · Psychological Medicine · doi:10.1017/s0033291712000955 · Cited by 301
“1992) or dexamethasone in a dose that would suppress elevated cortisol (Dinan et al. 1997).”
BackgroundThe human hypothalamus in mood disorders: The HPA axis in the center
Bao, A.-M., & Swaab, D. F. (2019) · IBRO Reports · doi:10.1016/j.ibror.2018.11.008 · Cited by 212
“sistant depression noticed a significant improvement in mood after receiving dexamethasone while remaining on their antidepressant (sertraline or fluoxetine) further supports the concept that hyperactive CRH neurons play a causal role in the symptomatology of depression (Dinan et al., 1997).”
Background
Metadata
- Authors
- Dinan, T. G., Lavelle, E., Cooney, J., Burnett, F., Scott, L., Dash, A., Thakore, J., & Berti, C.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 1997-01
- Volume
- 95
- Issue
- 1
- Pages
- 58-61
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2017644039
- Cited by
- 84
- References
- 1
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dexamethasone augmentation in treatment‐resistant depression. https://app.cochat.ai/papers/10.1111/j.1600-0447.1997.tb00374.x
- The paper
- Dinan, T. G., Lavelle, E., Cooney, J., Burnett, F., Scott, L., Dash, A., Thakore, J., & Berti, C. (1997). Dexamethasone augmentation in treatment‐resistant depression. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1997.tb00374.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.